Provident Trust Co. Has $627,000 Position in Johnson & Johnson (JNJ)

Provident Trust Co. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,858 shares of the company’s stock after selling 195 shares during the quarter. Johnson & Johnson accounts for about 0.0% of Provident Trust Co.’s investment portfolio, making the stock its 20th largest holding. Provident Trust Co.’s holdings in Johnson & Johnson were worth $627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of JNJ. Horan Securities Inc. lifted its holdings in Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after buying an additional 241 shares during the period. Stuart Chaussee & Associates Inc. lifted its holdings in Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 80 shares during the period. FNY Investment Advisers LLC lifted its holdings in Johnson & Johnson by 594.4% in the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after buying an additional 428 shares during the period. CKW Financial Group lifted its holdings in Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock worth $105,000 after buying an additional 128 shares during the period. Finally, Mackey Komara & Dankovich LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $148,000. Institutional investors own 67.20% of the company’s stock.

JNJ opened at $136.82 on Wednesday. The company has a market capitalization of $373.06 billion, a PE ratio of 16.73, a PEG ratio of 2.40 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The company had revenue of $20.02 billion during the quarter, compared to analysts’ expectations of $19.55 billion. During the same quarter last year, the business posted $2.06 EPS. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date is Friday, May 24th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s dividend payout ratio (DPR) is 44.01%.

A number of research analysts have recently commented on the company. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Morgan Stanley raised their target price on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 17th. Citigroup raised their target price on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research note on Monday, February 25th. Barclays restated an “equal weight” rating and issued a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Finally, BMO Capital Markets raised their target price on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $146.90.

WARNING: “Provident Trust Co. Has $627,000 Position in Johnson & Johnson (JNJ)” was first published by Rockland Register and is the sole property of of Rockland Register. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://rocklandregister.com/2019/05/15/provident-trust-co-has-627000-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Book Value Per Share in Stock Trading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.